stars 1 stars 2 stars 3

OTCPharm — is a major company on the Russian OTC market in terms of the range of pharmaceuticals in the main therapeutic categories. Feedback We are always glad to make our work even better. And always ready to answer your questions. Ask a question The Company was spun off from Pharmstandart at the end of 2013. OTCPharm currently holds the exclusive rights for more than 250 trademarks. The Company`s portfolio includes well-known brands: Arbidol®, Pentalgin®, Complivit®, Flucostat®, Aphobazolum®, Codelac®, Amixin®, Acipol®, Maxicold®, Rhinostop®, Magnelis® B6, Noopept®, Asvitol®, Ascophenum-P®, Next®, Lactazar®, Selmevit®, Termicon®, Lactonorm®, Cyclovita®, Cinocap®, Univit®, Nitrocor®, Neosmectin®, Klarisens®, Azitrox®, Gastrozol®, Mycoderil®, Escape®, Uronorm®, Aerovit® and Spasmol®. Along with promoting proprietary brands, OTCPharm is engaged in marketing and promoting drugs whose trademarks are owned by third parties. These products allow the Company to develop expertise in the respective categories. The company’s mission Our mission is to promote public health and a higher quality of life in the country. We employ advanced approaches and innovative solutions to develop medicines which are intended to enhance health and well-being. We aim to make pharmaceuticals safe and available for all who need them.

OTCPharm PJSC Questions

The OTCPharm PJSC annual revenue was $5 million in 2026.

Olga Mednikova is the CEO of OTCPharm PJSC.

30 people are employed at OTCPharm PJSC.

OTCPharm PJSC is based in Dolgoprudnyy, Moscow Oblast.

The NAICS codes for OTCPharm PJSC are [325, 3254, 62, 32, 62151, 6215, 621, 32541].

The SIC codes for OTCPharm PJSC are [283, 28].

G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users